Home › Companies › Kiniksa Pharmaceuticals International, plc › 2025-2026

Kiniksa Pharmaceuticals International, plc 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Kiniksa Pharmaceuticals International, plc’s Form 8-K, filed 2026-05-29 (Item 5.07 on EDGAR). Page generated 02 October 2026.

11Reported items
233Asset managers
1,660Fund votes
2026-05-29Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Kiniksa Pharmaceuticals International, plc in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Kiniksa Pharmaceuticals International, plc

These tallies are Kiniksa Pharmaceuticals International, plc’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Kiniksa Pharmaceuticals International, plc — official shareholder meeting results, meeting held 2026-05-29
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Stephen R. Biggar	37,474,114	11,999,916	13,825	--	4,425,771	Majority: yes
Elect Director: G. Bradley Cole	48,299,818	1,174,991	13,046	--	4,425,771	Majority: yes
Elect Director: Barry D. Quart	48,061,571	1,413,338	12,946	--	4,425,771	Majority: yes
Proposal 2 - To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's UK statutory auditors until the close of the Company's next Annual Meeting.	53,857,053	48,432	8,141	--	0	Majority: yes
Proposal 3 - To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2026.	53,857,126	48,355	8,145	--	0	Majority: yes
Proposal 5 - To receive the Company's UK statutory annual account and report for the period ended December 31, 2025.	53,611,179	2,032	300,415	--	0	Majority: yes
Proposal 6 - To approve, on an advisory non-binding basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2025.	48,353,142	1,104,811	29,902	--	4,425,771	Majority: yes
Proposal 7 - To approve the Company's UK Statutory Directors' Remuneration Policy.	48,633,937	824,799	29,119	--	4,425,771	Majority: yes
Proposal 8 - To approve, on an advisory non-binding basis, the compensation of the Company's named executive officers.	48,145,082	1,334,278	8,495	--	4,425,771	Majority: yes

Source: Kiniksa Pharmaceuticals International, plc, Form 8-K, filed with the SEC on 2026-05-29 — read the filing on EDGAR.

How asset managers voted at the Kiniksa Pharmaceuticals International, plc 2025-2026 meeting

Each item below shows how the 233 asset managers that disclosed a Kiniksa Pharmaceuticals International, plc vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Kiniksa Pharmaceuticals International, plc’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory (non- binding) basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 48,145,082AGAINST: 1,334,278

Kiniksa Pharmaceuticals International, plc’s own tally for this item (“Proposal 8 - To approve, on an advisory non-binding basis, the compensation of the Company's named executive officers.”): 48,145,082 for, 1,334,278 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 228 asset managers below cast 97% of the shares they voted on this item FOR (36,862,637 for, 1,201,611 against).

FOR 97%

FOR: 36,862,637 (96.8%)AGAINST: 1,201,611 (3.2%)ABSTAIN: 4,021 (0.0%)NOT VOTED: 500 (0.0%)

Largest asset managers voting on “To approve, on an advisory (non- binding) basis, the compensation of our named executive officers.” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Against	Vote
Fidelity	12,936,420	0	For
Rubric Capital Management LP	3,721,743	0	For
Vanguard	3,161,107	1	For
BAKER BROS. ADVISORS LP	2,855,926	0	For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	855,214	2,013	For
Victory Capital	833,723	0	For
DE Shaw	706,412	0	For
ACADIAN ASSET MANAGEMENT LLC	659,001	19,150	For
AllianceBernstein	663,124	0	For
Janus Henderson	598,200	0	For
PICTET ASSET MANAGEMENT SA	553,927	0	For
RICE HALL JAMES & ASSOCIATES, LLC	498,114	0	For
Aberdeen	0	497,456	Against
Soleus Capital Management, L.P.	459,212	0	For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	443,346	0	For
MFS	432,902	0	For
BlackRock	386,737	13,340	For
DRIEHAUS CAPITAL MANAGEMENT LLC	375,501	0	For
BALYASNY ASSET MANAGEMENT L.P.	344,355	0	For
Two Sigma	331,802	0	For
Point72	311,799	0	For
Dimensional	311,329	0	For
ArrowMark Colorado Holdings LLC	291,210	0	For
Citadel	290,639	0	For
AQR	264,651	0	For

Showing the 25 largest of 228 asset managers. See all 228 in the interactive database.

2. To approve, on an advisory (non-binding) basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2025.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,353,142AGAINST: 1,104,811

Kiniksa Pharmaceuticals International, plc’s own tally for this item (“Proposal 6 - To approve, on an advisory non-binding basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2025.”): 48,353,142 for, 1,104,811 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 115 asset managers below cast 99% of the shares they voted on this item FOR (19,413,454 for, 199,467 against).

FOR 98%

FOR: 19,413,454 (98.2%)AGAINST: 199,467 (1.0%)ABSTAIN: 164,021 (0.8%)

Largest asset managers voting on “To approve, on an advisory (non-binding) basis, the Company's UK Statutory Directors' Annual Remuneration Repo” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	6,157,387	0	0	For
Rubric Capital Management LP	3,721,743	0	0	For
Vanguard	3,093,980	1	0	For
BAKER BROS. ADVISORS LP	2,855,926	0	0	For
Soleus Capital Management, L.P.	459,212	0	0	For
MFS	432,902	0	0	For
BlackRock	386,737	13,340	0	For
Victory Capital	382,503	0	0	For
Dimensional	226,131	0	0	For
ORBIMED ADVISORS LLC	180,599	0	0	For
CASTLEARK MANAGEMENT LLC	161,830	0	0	For
HUSSMAN INVESTMENT TRUST	0	0	160,000	Abstain
Aberdeen	0	146,045	0	Against
DRIEHAUS MUTUAL FUNDS	97,649	0	0	For
Allspring	92,155	0	0	For
AllianceBernstein	86,090	0	0	For
PNC BANK, NATIONAL ASSOCIATION	86,000	0	0	For
SILVERCREST ASSET MANAGEMENT GROUP LLC	75,276	0	0	For
Voya	72,099	0	0	For
DWS	61,175	0	0	For
CLEARWATER INVESTMENT TRUST	60,310	0	0	For
Innovator ETFs Trust	55,893	0	0	For
OPTIMUM FUND TRUST	53,513	0	0	For
Charles Schwab	49,008	0	0	For
Northern Trust	45,273	2,800	0	For

Showing the 25 largest of 115 asset managers. See all 115 in the interactive database.

3. TO APPROVE THE COMPANY'S UK STATUTORY DIRECTORS' REMUNERATION POLICY.

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,633,937AGAINST: 824,799

Kiniksa Pharmaceuticals International, plc’s own tally for this item (“Proposal 7 - To approve the Company's UK Statutory Directors' Remuneration Policy.”): 48,633,937 for, 824,799 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 62 asset managers below cast 99% of the shares they voted on this item FOR (12,095,643 for, 162,063 against).

FOR 97%

FOR: 12,095,643 (97.4%)AGAINST: 162,063 (1.3%)ABSTAIN: 160,000 (1.3%)

Largest asset managers voting on “TO APPROVE THE COMPANY'S UK STATUTORY DIRECTORS' REMUNERATION POLICY.” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	6,157,387	0	0	For
Vanguard	3,093,981	0	0	For
MFS	432,902	0	0	For
BlackRock	385,910	13,340	0	For
Victory Capital	382,503	0	0	For
ESSEX INVESTMENT MANAGEMENT CO LLC	323,940	0	0	For
Dimensional	226,131	0	0	For
HUSSMAN INVESTMENT TRUST	0	0	160,000	Abstain
Aberdeen	0	146,045	0	Against
DRIEHAUS MUTUAL FUNDS	97,649	0	0	For
Allspring	92,155	0	0	For
AllianceBernstein	86,090	0	0	For
Voya	72,099	0	0	For
DWS	61,175	0	0	For
CLEARWATER INVESTMENT TRUST	60,310	0	0	For
Innovator ETFs Trust	55,893	0	0	For
OPTIMUM FUND TRUST	53,513	0	0	For
Charles Schwab	49,008	0	0	For
RBB FUND, INC.	47,115	0	0	For
1290 Funds	40,372	0	0	For
Northern Lights Fund Trust IV	35,271	0	0	For
Empower	30,896	0	0	For
MERIDIAN FUND INC	30,758	0	0	For
Invesco	27,015	0	0	For
RBB Fund Trust	23,955	0	0	For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

4. Election of Class II Directors to serve until the 2029 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Barry D. Quart

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 48,061,571AGAINST: 1,413,338

Kiniksa Pharmaceuticals International, plc’s own tally for this item (“Elect Director: Barry D. Quart”): 48,061,571 for, 1,413,338 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 58 asset managers below cast 97% of the shares they voted on this item FOR (11,456,128 for, 321,063 against).

FOR 97%

FOR: 11,456,128 (97.3%)AGAINST: 321,063 (2.7%)

Largest asset managers voting on “Election of Class II Directors to serve until the 2029 Annual General Meeting of Shareholders, and until their” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Against	Vote
Fidelity	6,157,387	0	For
Vanguard	3,093,980	1	For
MFS	432,902	0	For
Victory Capital	382,503	0	For
Dimensional	0	226,131	Against
HUSSMAN INVESTMENT TRUST	160,000	0	For
Aberdeen	146,045	0	For
DRIEHAUS MUTUAL FUNDS	97,649	0	For
BlackRock	94,825	0	For
Allspring	92,155	0	For
AllianceBernstein	86,090	0	For
Voya	0	72,099	Against
DWS	61,175	0	For
CLEARWATER INVESTMENT TRUST	60,310	0	For
Innovator ETFs Trust	55,893	0	For
OPTIMUM FUND TRUST	53,513	0	For
Charles Schwab	49,008	0	For
RBB FUND, INC.	47,115	0	For
1290 Funds	40,372	0	For
Northern Lights Fund Trust IV	35,271	0	For
Empower	30,896	0	For
MERIDIAN FUND INC	30,758	0	For
Invesco	27,015	0	For
RBB Fund Trust	23,955	0	For
Jackson National	14,048	8,565	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

5. Election of Class II Directors to serve until the 2029 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: G. Bradley Cole

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 48,299,818AGAINST: 1,174,991

Kiniksa Pharmaceuticals International, plc’s own tally for this item (“Elect Director: G. Bradley Cole”): 48,299,818 for, 1,174,991 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 58 asset managers below cast 97% of the shares they voted on this item FOR (11,456,347 for, 320,844 against).

FOR 97%

FOR: 11,456,347 (97.3%)AGAINST: 320,844 (2.7%)

Largest asset managers voting on “Election of Class II Directors to serve until the 2029 Annual General Meeting of Shareholders, and until their” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Against	Vote
Fidelity	6,157,387	0	For
Vanguard	3,093,980	1	For
MFS	432,902	0	For
Victory Capital	382,503	0	For
Dimensional	0	226,131	Against
HUSSMAN INVESTMENT TRUST	160,000	0	For
Aberdeen	146,045	0	For
DRIEHAUS MUTUAL FUNDS	97,649	0	For
BlackRock	94,825	0	For
Allspring	92,155	0	For
AllianceBernstein	86,090	0	For
Voya	0	72,099	Against
DWS	61,175	0	For
CLEARWATER INVESTMENT TRUST	60,310	0	For
Innovator ETFs Trust	55,893	0	For
OPTIMUM FUND TRUST	53,513	0	For
Charles Schwab	49,008	0	For
RBB FUND, INC.	47,115	0	For
1290 Funds	40,372	0	For
Northern Lights Fund Trust IV	35,271	0	For
Empower	30,896	0	For
MERIDIAN FUND INC	30,758	0	For
Invesco	27,015	0	For
RBB Fund Trust	23,955	0	For
Jackson National	14,048	8,565	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

6. Election of Class II Directors to serve until the 2029 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Stephen R. Biggar

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%AGAINST 24%

FOR: 37,474,114AGAINST: 11,999,916

Kiniksa Pharmaceuticals International, plc’s own tally for this item (“Elect Director: Stephen R. Biggar”): 37,474,114 for, 11,999,916 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 58 asset managers below cast 82% of the shares they voted on this item FOR (9,712,176 for, 2,065,014 against).

FOR 82%AGAINST 18%

FOR: 9,712,176 (82.5%)AGAINST: 2,065,014 (17.5%)

Largest asset managers voting on “Election of Class II Directors to serve until the 2029 Annual General Meeting of Shareholders, and until their” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Against	Vote
Fidelity	6,113,277	44,110	For
Vanguard	3,074,617	19,363	For
MFS	0	432,902	Against
Victory Capital	0	382,503	Against
Dimensional	0	226,131	Against
HUSSMAN INVESTMENT TRUST	160,000	0	For
Aberdeen	0	146,045	Against
DRIEHAUS MUTUAL FUNDS	0	97,649	Against
BlackRock	94,825	0	For
Allspring	0	92,155	Against
AllianceBernstein	0	86,090	Against
Voya	0	72,099	Against
DWS	0	61,175	Against
CLEARWATER INVESTMENT TRUST	0	60,310	Against
Innovator ETFs Trust	55,893	0	For
OPTIMUM FUND TRUST	53,513	0	For
Charles Schwab	0	49,008	Against
RBB FUND, INC.	0	47,115	Against
1290 Funds	0	40,372	Against
Northern Lights Fund Trust IV	35,271	0	For
Empower	30,896	0	For
MERIDIAN FUND INC	0	30,758	Against
Invesco	27,015	0	For
RBB Fund Trust	23,955	0	For
Jackson National	0	22,613	Against

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

7. To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's UK statutory auditors until the close of the 2027 Annual General Meeting of Shareholders.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 53,857,053AGAINST: 48,432

Kiniksa Pharmaceuticals International, plc’s own tally for this item (“Proposal 2 - To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's UK statutory auditors until the close of the Company's next Annual Meeting.”): 53,857,053 for, 48,432 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 58 asset managers below cast 100% of the shares they voted on this item FOR (11,777,191 for, 0 against).

FOR 100%

FOR: 11,777,191 (100.0%)

Largest asset managers voting on “To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's UK statutory auditors until ” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Vote
Fidelity	6,157,387	For
Vanguard	3,093,981	For
MFS	432,902	For
Victory Capital	382,503	For
Dimensional	226,131	For
HUSSMAN INVESTMENT TRUST	160,000	For
Aberdeen	146,045	For
DRIEHAUS MUTUAL FUNDS	97,649	For
BlackRock	94,825	For
Allspring	92,155	For
AllianceBernstein	86,090	For
Voya	72,099	For
DWS	61,175	For
CLEARWATER INVESTMENT TRUST	60,310	For
Innovator ETFs Trust	55,893	For
OPTIMUM FUND TRUST	53,513	For
Charles Schwab	49,008	For
RBB FUND, INC.	47,115	For
1290 Funds	40,372	For
Northern Lights Fund Trust IV	35,271	For
Empower	30,896	For
MERIDIAN FUND INC	30,758	For
Invesco	27,015	For
RBB Fund Trust	23,955	For
Jackson National	22,613	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

8. To authorize the Company's Board of Directors, through its Audit Committee, to determine PwC's remuneration in its capacity as our UK statutory auditors until the close of the 2027 Annual General Meeting of Shareholders.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 57 asset managers below cast 100% of the shares they voted on this item FOR (11,776,271 for, 0 against).

FOR: 11,776,271 (100.0%)

Largest asset managers voting on “To authorize the Company's Board of Directors, through its Audit Committee, to determine PwC's remuneration in” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Vote
Fidelity	6,157,387	For
Vanguard	3,093,981	For
MFS	432,902	For
Victory Capital	382,503	For
Dimensional	226,131	For
HUSSMAN INVESTMENT TRUST	160,000	For
Aberdeen	146,045	For
DRIEHAUS MUTUAL FUNDS	97,649	For
BlackRock	94,825	For
Allspring	92,155	For
AllianceBernstein	86,090	For
Voya	72,099	For
DWS	61,175	For
CLEARWATER INVESTMENT TRUST	60,310	For
Innovator ETFs Trust	55,893	For
OPTIMUM FUND TRUST	53,513	For
Charles Schwab	49,008	For
RBB FUND, INC.	47,115	For
1290 Funds	40,372	For
Northern Lights Fund Trust IV	35,271	For
Empower	30,896	For
MERIDIAN FUND INC	30,758	For
Invesco	27,015	For
RBB Fund Trust	23,955	For
Jackson National	22,613	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

9. To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 53,857,126AGAINST: 48,355

Kiniksa Pharmaceuticals International, plc’s own tally for this item (“Proposal 3 - To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 53,857,126 for, 48,355 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 57 asset managers below cast 100% of the shares they voted on this item FOR (11,776,271 for, 0 against).

FOR 100%

FOR: 11,776,271 (100.0%)

Largest asset managers voting on “To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fis” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Vote
Fidelity	6,157,387	For
Vanguard	3,093,981	For
MFS	432,902	For
Victory Capital	382,503	For
Dimensional	226,131	For
HUSSMAN INVESTMENT TRUST	160,000	For
Aberdeen	146,045	For
DRIEHAUS MUTUAL FUNDS	97,649	For
BlackRock	94,825	For
Allspring	92,155	For
AllianceBernstein	86,090	For
Voya	72,099	For
DWS	61,175	For
CLEARWATER INVESTMENT TRUST	60,310	For
Innovator ETFs Trust	55,893	For
OPTIMUM FUND TRUST	53,513	For
Charles Schwab	49,008	For
RBB FUND, INC.	47,115	For
1290 Funds	40,372	For
Northern Lights Fund Trust IV	35,271	For
Empower	30,896	For
MERIDIAN FUND INC	30,758	For
Invesco	27,015	For
RBB Fund Trust	23,955	For
Jackson National	22,613	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

10. TO RECEIVE THE COMPANY'S UK STATUTORY ANNUAL ACCOUNTS AND REPORT FOR THE PERIOD ENDED DECEMBER 31, 2025.

CORPORATE GOVERNANCEMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 53,611,179AGAINST: 2,032

Kiniksa Pharmaceuticals International, plc’s own tally for this item (“Proposal 5 - To receive the Company's UK statutory annual account and report for the period ended December 31, 2025.”): 53,611,179 for, 2,032 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 57 asset managers below cast 100% of the shares they voted on this item FOR (11,776,271 for, 0 against).

FOR 100%

FOR: 11,776,271 (100.0%)

Largest asset managers voting on “TO RECEIVE THE COMPANY'S UK STATUTORY ANNUAL ACCOUNTS AND REPORT FOR THE PERIOD ENDED DECEMBER 31, 2025.” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Vote
Fidelity	6,157,387	For
Vanguard	3,093,981	For
MFS	432,902	For
Victory Capital	382,503	For
Dimensional	226,131	For
HUSSMAN INVESTMENT TRUST	160,000	For
Aberdeen	146,045	For
DRIEHAUS MUTUAL FUNDS	97,649	For
BlackRock	94,825	For
Allspring	92,155	For
AllianceBernstein	86,090	For
Voya	72,099	For
DWS	61,175	For
CLEARWATER INVESTMENT TRUST	60,310	For
Innovator ETFs Trust	55,893	For
OPTIMUM FUND TRUST	53,513	For
Charles Schwab	49,008	For
RBB FUND, INC.	47,115	For
1290 Funds	40,372	For
Northern Lights Fund Trust IV	35,271	For
Empower	30,896	For
MERIDIAN FUND INC	30,758	For
Invesco	27,015	For
RBB Fund Trust	23,955	For
Jackson National	22,613	For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

11. Accept Financial Statements and Statutory Reports

CORPORATE GOVERNANCE

17% fund support · no official result

FOR 17%AGAINST 83%

The 2 asset managers below cast 17% of the shares they voted on this item FOR (920 for, 4,400 against).

FOR: 920 (17.3%)AGAINST: 4,400 (82.7%)

Largest asset managers voting on “Accept Financial Statements and Statutory Reports” at Kiniksa Pharmaceuticals International, plc, 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
FORUM FUNDS II	0	4,400	0	0	Against
FORUM FUNDS	920	0	0	0	For

Largest Kiniksa Pharmaceuticals International, plc shareholders voting in 2025-2026

Ranked by the number of Kiniksa Pharmaceuticals International, plc shares each manager voted on the most widely held ballot item of the 2025-2026 meeting.

Top Kiniksa Pharmaceuticals International, plc shareholders by shares voted, 2025-2026
#	Asset manager	Shares voted
1	Fidelity	12,936,420
2	Rubric Capital Management LP	3,721,743
3	Vanguard	3,161,108
4	BAKER BROS. ADVISORS LP	2,855,926
5	ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	857,227
6	Victory Capital	833,723
7	DE Shaw	706,412
8	ACADIAN ASSET MANAGEMENT LLC	678,151
9	AllianceBernstein	663,124
10	Janus Henderson	598,200

Shown as share counts, not percentages: no shares-outstanding figure has been matched to Kiniksa Pharmaceuticals International, plc for the 2025-2026 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Kiniksa Pharmaceuticals International, plc's shareholder meeting held 2026-05-29, in the 2025-2026 proxy season, 233 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,660 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory (non- binding) basis, the compensation of our named executive… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Kiniksa Pharmaceuticals International, plc's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-29.

Kiniksa Pharmaceuticals International, plc proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).